4.6 Article

Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

Journal

THORAX
Volume 77, Issue 6, Pages 606-615

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2021-217629

Keywords

-

Funding

  1. National Institute for Health Research (NIHR) [CO-CIN-01]
  2. Medical Research Council [MC_ PC_19059]
  3. NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool
  4. Public Health England (PHE)
  5. Liverpool School of Tropical Medicine
  6. University of Oxford [200 907]
  7. NIHR HPRU in Respiratory Infections at Imperial College London
  8. Wellcome Trust [205228/Z/16/Z]
  9. Department for International Development [215091/Z/18/Z]
  10. Bill and Melinda Gates Foundation [OPP1209135]
  11. Liverpool Experimental Cancer Medicine Centre [C18616/A25153]
  12. NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013]
  13. EU Platform foR European Preparedness Against (Re-) emerging Epidemics (PREPARE) (FP7 project) [602 525]
  14. NIHR [201 385]
  15. WT investigator award [207511/Z/17/Z]
  16. NIHR University College London Hospitals Biomedical Research Centre
  17. PHE [200 927]
  18. NIHR Clinical Research Network

Ask authors/readers for more resources

This study prospectively validated two risk scores for predicting mortality and in-hospital deterioration among adults hospitalized with COVID-19 in the UK. The 4C Mortality and 4C Deterioration scores demonstrated consistent discrimination across all NHS regions and stable calibration during the second wave of the pandemic. These risk stratification models can continue to inform clinical decision making for COVID-19 patients.
Purpose To prospectively validate two risk scores to predict mortality (4C Mortality) and in-hospital deterioration (4C Deterioration) among adults hospitalised with COVID-19. Methods Prospective observational cohort study of adults (age >= 18 years) with confirmed or highly suspected COVID-19 recruited into the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study in 306 hospitals across England, Scotland and Wales. Patients were recruited between 27 August 2020 and 17 February 2021, with at least 4 weeks follow-up before final data extraction. The main outcome measures were discrimination and calibration of models for in-hospital deterioration (defined as any requirement of ventilatory support or critical care, or death) and mortality, incorporating predefined subgroups. Results 76 588 participants were included, of whom 27 352 (37.4%) deteriorated and 12 581 (17.4%) died. Both the 4C Mortality (0.78 (0.77 to 0.78)) and 4C Deterioration scores (pooled C-statistic 0.76 (95% CI 0.75 to 0.77)) demonstrated consistent discrimination across all nine National Health Service regions, with similar performance metrics to the original validation cohorts. Calibration remained stable (4C Mortality: pooled slope 1.09, pooled calibration-in-the-large 0.12; 4C Deterioration: 1.00, -0.04), with no need for temporal recalibration during the second UK pandemic wave of hospital admissions. Conclusion Both 4C risk stratification models demonstrate consistent performance to predict clinical deterioration and mortality in a large prospective second wave validation cohort of UK patients. Despite recent advances in the treatment and management of adults hospitalised with COVID-19, both scores can continue to inform clinical decision making.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available